Hantavirus: Rodent Reservoirs and the Dangerous Andes Strain

The Andes strain of hantavirus has re-emerged as a critical public health concern in South America, where eight distinct wild rodent species act as silent vectors for transmission. While the virus remains rare in global terms, its potential for person-to-person spread—unlike most hantaviruses—and its severe pulmonary manifestations demand urgent attention from clinicians, epidemiologists, and public health systems. Argentina, in particular, grapples with endemic reservoirs of infected rodents, yet critical gaps persist in surveillance, vector ecology, and clinical preparedness. This analysis synthesizes the latest epidemiological data, mechanistic insights, and actionable triage pathways for healthcare providers navigating this evolving threat.

Key Clinical Takeaways:

• Eight rodent species in Argentina—including the long-tailed mouse (*Phyllotis xanthopygus*)—serve as primary reservoirs for the Andes hantavirus strain, with transmission risk tied to urban encroachment on rodent habitats.
• Person-to-person spread of Andes virus is documented but rare, requiring heightened vigilance in healthcare settings where aerosolized exposure (e.g., coughing, close contact) may occur.
• Early symptoms mimic influenza, but progression to hantavirus pulmonary syndrome (HPS) carries a 30–50% mortality rate without rapid intervention, necessitating differential diagnosis protocols.

Rodent Reservoirs and Viral Ecology: The Eight Species Driving Transmission

Argentina’s hantavirus epidemiology is dominated by eight wild rodent species, each with distinct ecological niches and viral shedding patterns. The long-tailed mouse (Oligoryzomys longicaudatus)—commonly referred to as the “colilargo”—emerges as the primary reservoir, harboring the Andes virus strain responsible for the majority of human cases. According to a 2024 study published in Emerging Infectious Diseases (funded by the Argentine Ministry of Health and CONICET), only 2–5% of colilargo populations test positive for the virus, yet their high population density in agricultural and peri-urban zones amplifies human exposure risks. The study’s lead author, Dr. Valeria Zylberman (PhD, Institute of Ecology and Evolutionary Biology, UBA), clarifies:

“The misconception that all colilargos carry hantavirus obscures the true risk: it’s not the rodents themselves that are dangerous, but the environmental contamination they leave behind. Urine and feces can remain infectious for weeks, particularly in poorly ventilated structures like silos, sheds, or abandoned homes.”

The remaining seven species—Calomys musculinus, Akodon azarae, Oligoryzomys flavescens, Oligoryzomys chacoensis, Abrothrix andinus, Akodon boliviensis, and Akodon spegazzinii—contribute to regional transmission dynamics, though their viral loads and host competency vary. A 2025 meta-analysis in Vector-Borne and Zoonotic Diseases (NIH-funded) revealed that Calomys musculinus exhibits higher viral RNA titers in saliva than other species, suggesting a potential underappreciated role in aerosol transmission.

Pathogenesis and Clinical Trajectories: From Flu-Like Onset to Pulmonary Collapse

The Andes virus’s pathogenesis hinges on its ability to evade innate immunity via the α-dystroglycan receptor, a mechanism distinct from other hantaviruses. Once internalized, the virus triggers a cytokine storm in alveolar macrophages, leading to capillary leak syndrome—a hallmark of hantavirus pulmonary syndrome (HPS). The incubation period spans 4–42 days, with early symptoms (fever, myalgia, gastrointestinal distress) overlapping with influenza, dengue, or leptospirosis. The critical diagnostic window closes when patients progress to late-stage HPS:

• Days 4–10: Cough evolves into non-cardiogenic pulmonary edema, with chest X-rays revealing diffuse infiltrates.
• Days 10–14: Hypotension and hemoconcentration signal multiorgan failure, with mortality peaking at 36–48 hours post-edema onset.

Per the CDC’s 2026 Andes virus clinical brief, person-to-person transmission is documented in only 12 confirmed clusters globally, primarily in healthcare settings where aerosol-generating procedures (e.g., intubation) were performed without airborne precautions. The basic reproduction number (R₀) for human transmission remains below 1.2, but nosocomial outbreaks in Argentina’s rural clinics underscore the need for universal droplet/airborne precautions for suspected cases.

Epidemiological Gaps and the Surveillance Deficit

Argentina’s hantavirus surveillance system—rooted in passive case reporting—fails to capture subclinical infections or early-stage outbreaks. A 2023 study in PLOS Neglected Tropical Diseases (Wellcome Trust-funded) estimated that only 1 in 10 HPS cases are diagnosed, with rural provinces like Chubut and Río Negro reporting underreporting rates exceeding 60%. The absence of rapid antigen tests further delays treatment, as PCR confirmation requires centralized labs with turnaround times of 48–72 hours.

Clinicians must navigate additional challenges:

• Diagnostic ambiguity: Serological cross-reactivity with other hantaviruses (e.g., Seoul virus) complicates seroprevalence studies.
• Therapeutic limitations: Ribavirin, the sole FDA-approved antiviral, shows mixed efficacy in Andes HPS (per a 2022 Journal of Infectious Diseases trial with N=47), with optimal dosing protocols still debated.
• Vector ecology data gaps: Climate models predict a 20–30% expansion of colilargo habitats by 2050 due to deforestation, yet no national rodent surveillance program exists.

Triage and Actionable Pathways for Clinicians

For patients presenting with fever + large-muscle myalgia + gastrointestinal symptoms in hantavirus-endemic regions, immediate triage is critical. The following protocols align with WHO’s 2025 HPS management guidelines:

1. Rule out differentials: Rapid tests for dengue, leptospirosis, and influenza must precede hantavirus PCR. Specialized infectious disease labs offering multiplex PCR panels can reduce diagnostic delays.
2. Isolate and implement airborne precautions: Suspected HPS patients require negative-pressure rooms. Hospitals should consult infection control specialists to audit ventilation systems.
3. Monitor for pulmonary edema: Continuous pulse oximetry and daily chest X-rays are essential. Early administration of high-flow oxygen (via non-rebreather mask) may mitigate progression to ARDS.

Healthcare systems in Argentina’s rural zones face acute shortages of ICU beds and ventilators. The Pan American Health Organization (PAHO) recommends partnering with telemedicine networks to facilitate remote consultations with pulmonologists during outbreaks.

The Future: Vaccines, One Health, and Clinical Readiness

Two vaccine candidates are in advanced stages of development:

Yet vaccines alone cannot address the root cause: the One Health nexus of rodent ecology, human behavior, and climate change. Public health strategies must integrate:

• Rodent-proofing infrastructure: Retrofitting homes and agricultural storage with specialized sealing services.
• Community education: Training local health workers to recognize early symptoms and enforce 24-hour rodent exclusion protocols in outbreak zones.
• Surveillance innovation: Deploying environmental DNA (eDNA) monitoring to detect viral shedding in rodent populations.

The next decade will test Argentina’s ability to balance ecological preservation with public health resilience. Clinicians and epidemiologists must collaborate with One Health consultants to design adaptive strategies—before the next outbreak exposes systemic vulnerabilities.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.